Is "Ozempic Microdosing" Real? The Actual Dose Chart, Cost, and Where It's Sold

Where can you get an Ozempic-style microdose? The four options, one by one

None of these sells Ozempic. Each sells compounded semaglutide, the medicine inside Ozempic, made by a pharmacy at a low dose. Compounded means a pharmacy mixes it for one patient, and it is not FDA-approved. Start with the line that sounds like you:

• Lowest price: Mochi Health, about $140 a month at the lowest dose.
• You want coaching with it: Noom, about $180 a month, billed every 12 weeks.
• Wellness, not weight loss: Fridays, though its benefits are unproven.
• You have type 2 diabetes and insurance: skip microdosing. Brand-name Ozempic with Novo Nordisk's savings card can cost as little as $25 a month.

Mochi Health: the lowest monthly price

Mochi has a microdosing plan for compounded semaglutide. It is simply the cheapest step of its normal price ladder, since Mochi prices medicine by dose. Semaglutide starts at about $60 a month, and the membership adds about $80. The first month of membership is free on the monthly plan.

Mochi now works as a pharmacy marketplace, so these are floor prices that can vary by pharmacy. Paying a year of membership upfront brings the lowest dose to about $110 a month. Our Mochi Health review covers its pharmacies and reputation.

Noom: a microdose plan with a coaching app

Noom sells Microdose GLP-1Rx, a plan separate from its standard semaglutide plan. Noom defines a microdose as 25% or less of a typical maintenance dose. The first four weeks cost $79. After that it is about $180 a month, but Noom bills about $535 every 12 weeks, so budget for that lump sum.

In May 2026, the National Advertising Division, the ad industry's watchdog, reviewed Noom's slogan "A Smaller Dose. A Smarter Start." It found the implied health benefit was not backed up and asked Noom to change or drop it.

Henry Meds: a microdose page, price set by plan

Henry Meds has a microdose page for compounded semaglutide shots. It says prices vary by plan and dose and start at $179 a month, with visits, medicine and supplies included. That $179 is Henry's general starting price, so ask for the microdose price on your plan before you pay.

Fridays: a microdose sold for wellness

Fridays sells a daily oral semaglutide blend in a separate Microdosing section, for about $250 a month. It markets it for energy and metabolic balance, not weight loss. Its own page says these compounded microdose formulas have not been studied for those outcomes. Our Fridays review covers the rest of its program.

For more providers, including a brand-name Wegovy pill plan, see semaglutide microdosing.

Is "Ozempic microdosing" a real product?

No. Ozempic is Novo Nordisk's brand of semaglutide, FDA-approved in 2017 for adults with type 2 diabetes. Novo Nordisk has never sold a smaller microdose version. No pharmacy can legally make a copy and call it Ozempic, because the brand name covers the finished product.

Novo Nordisk defends that line in court. In April 2025, it won a permanent injunction against one compounding pharmacy that sold knockoffs under the Ozempic name. So a seller that calls its product "Ozempic microdosing" is a warning sign. Legitimate sellers say compounded semaglutide.

For the wider legal picture on compounded versions, see compounded Ozempic.

What does the real Ozempic dose chart show?

Ozempic's label has no dose below 0.25 mg. Its schedule climbs up, not down. The slow start is there to ease nausea on the way to a dose that controls blood sugar.

A real "Ozempic microdosing chart" would need a smaller, ongoing dose. The label does not have one. For the full schedule, including the pill and missed doses, see the Ozempic dosage guide.

What does microdosing cost compared with real Ozempic?

Brand-name Ozempic has five price paths. Your insurance and diagnosis decide which one is yours.

• With insurance and type 2 diabetes: as little as $25 a month with Novo Nordisk's savings card. The card takes off at most $100 a month.
• Ozempic pill, no insurance: about $150 to $300 a month on NovoCare, Novo Nordisk's self-pay program. The price rises with the dose.
• Ozempic pen, no insurance: about $350 a month up to 1 mg and about $500 at 2 mg on NovoCare. New patients pay about $200 for their first two fills through Dec 31, 2026.
• On Medicare: your Part D plan's copay if it covers Ozempic for diabetes. Drug costs stop at $2,100 a year in 2026. Medicare's $50 GLP-1 Bridge does not cover Ozempic.
• List price, no program: about $1,000 a month. It is set to drop to $675 on Jan. 1, 2027.

Compounded microdoses cost less than the NovoCare pen but are not Ozempic. Here is a rough first year at a steady low dose:

• Mochi Health: about $1,600 to $1,700 at the lowest dose, or about $1,300 with a prepaid year of membership.
• Noom: about $2,230, counting the $79 start and four 12-week bills.
• Henry Meds: about $2,150 at its $179 starting price. Your microdose plan may differ.
• Fridays: about $3,000.
• NovoCare Ozempic pen: about $4,240 in the first year at doses up to 1 mg, with 13 four-week fills.

None of these totals include lab tests. For every Ozempic price path, see Ozempic cost.

Can you just dial your Ozempic pen lower?

No. Ozempic comes in a multi-dose pen with a dial, unlike Wegovy's single-dose pen. But each Ozempic pen only dials the doses printed on it. The lowest setting on any Ozempic pen is 0.25 mg.

So the closest thing to microdosing a real Ozempic pen is staying on 0.25 mg past the first four weeks. That is an off-label choice about timing, not a smaller dose. Drawing medicine out of a pen in other ways is not what the device is made for.

Does science back a lower-than-labeled Ozempic dose?

For blood sugar, the trials point the other way. In SUSTAIN 4, A1C fell about 1.6 points on 1 mg, against about 1.2 points on 0.5 mg. In SUSTAIN FORTE, 2 mg lowered A1C a bit more than 1 mg. No trial has tested staying below 0.25 mg.

For weight, the evidence on microdosing is thin. Harvard endocrinologist Dr. Jody Dushay wrote in STAT News in May 2026 that there are no legitimate long-term data behind it. One registered trial of microdosed semaglutide is running, with no results posted yet.

Are side effects gentler at a lower dose?

Maybe, but it is not proven. Nausea tends to cluster right after each dose increase, which is why the label climbs slowly. A smaller, steady dose could mean fewer of those rough weeks.

Some doctors doubt it. Endocrinologist Dr. Ritu Anand told Hackensack Meridian Health in May 2026 that each new small step can feel like starting over, with side effects coming back. And if blood sugar control is your goal, staying well under 0.5 mg works against the trial evidence.

Does microdosing make sense in perimenopause with prediabetes?

If you searched for Ozempic, not Wegovy, a prediabetes or type 2 diabetes diagnosis may have brought you here. Falling estrogen around menopause is linked to lower insulin sensitivity, so blood sugar can creep up in your forties.

That changes what a lower dose is for. A slower climb toward an effective dose, to ease side effects, is a normal question for your prescriber. Staying at a fraction of the dose for good runs against the evidence for blood sugar.

If weight is part of the picture, see GLP-1 medications and menopause weight gain. Muscle matters more after 40, and GLP-1s and muscle loss in perimenopause covers how to protect it.

How to tell a legitimate low-dose plan from a DIY red flag

What matters most is who manages the dose. A legitimate plan comes from a licensed prescriber and a named compounding pharmacy. Your provider sets the dose and can change it.

Red flags look different. The product is sold as "Ozempic microdosing." The pharmacy has no name. Or the seller suggests splitting a real Ozempic pen yourself.

The FDA has issued an alert on compounded semaglutide dosing errors. Most reports involved patients drawing too much from a multi-dose vial. Some injected 5 to 20 times their intended dose, and some needed hospital care.

Compounded semaglutide is legal when a licensed pharmacy makes it for one patient on a prescription. The FDA ended the semaglutide shortage in February 2025, which ended mass compounding. On April 30, 2026, the FDA also proposed not adding semaglutide to the list that large outsourcing pharmacies, called 503B, can compound from. Comments closed July 30, 2026, with no final decision yet.